Latest for ALK-Positive Lung Cancer
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
More about ALK-Positive Lung Cancer
The fused gene makes a protein that keeps telling the cells to grow, according to LUNGevity and the National Cancer Institute. The change happens during life in the tumor only and is not passed on in families.
Keep reading about ALK-Positive Lung Cancer
The ALK change is found by testing the tumor. ALK Positive says experts recommend next-generation sequencing (NGS) as part of any biomarker testing, because FISH and immunohistochemistry check only a few gene changes. It also says US guidelines recommend comprehensive biomarker testing for everyone diagnosed with non-small cell lung cancer. LUNGevity calls a tissue biopsy the standard when enough tissue is available. The Alecensa label says that when a blood test does not find an ALK change, tumor tissue should be tested if possible. ALK-positive lung cancer often spreads to the brain. In a 2015 Boston study from before the newer ALK drugs, 23.8% of 21 people with advanced ALK-positive cancer had brain metastases when advanced disease was found. Among those still alive at 3 years, 58.4% had them (Rangachari et al., 2015).
The main treatment for advanced disease is a daily ALK inhibitor pill. The American Cancer Society says lorlatinib, alectinib, brigatinib, ceritinib and ensartinib are often the preferred first treatment. It says alectinib is also used after surgery for some early-stage cancers. It adds that crizotinib, the first of these drugs, is still used in some situations. Over time the cancer often changes the ALK protein in ways that stop a drug from working. Each drug tends to leave behind its own resistance changes, such as G1202R (Gainor et al., 2016). This is why LUNGevity says doctors often recommend a new biopsy before switching. On November 17, 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced cancer. It is for adults whose cancer grew after alectinib alone, or after 2 or more ALK inhibitors and platinum chemotherapy, given for advanced or metastatic disease.
What are the symptoms of ALK-Positive Lung Cancer?
These are common symptoms of ALK-Positive Lung Cancer, and how strong they are varies from person to person.
- A cough that does not go away or gets worse
- Chest pain or discomfort, and trouble breathing or wheezing
- Coughing up blood, or hoarseness
- Tiredness, loss of appetite and weight loss without a known reason
- Headaches, weakness or seizures if the cancer has spread to the brain
- No symptoms at all until the cancer has spread, which ALK Positive says is common
Who gets ALK-Positive Lung Cancer?
ALK-positive lung cancer is usually found at a younger age than lung cancer overall. LUNGevity gives a median age at diagnosis of 52 for ALK-positive non-small cell lung cancer. The median age was 56 among the 656 people in the trial behind the Nelkarmi approval, according to its label. For comparison, the American Cancer Society puts the average age at diagnosis for all lung cancer at about 70. ALK Positive says 2 out of 3 people with ALK-positive lung cancer never smoked. The National Cancer Institute says EGFR and ALK changes predominate in adenocarcinomas that develop in nonsmokers. The ALK change is acquired in the tumor and is not inherited, according to LUNGevity.
Next steps: find trials you might fitcompare treatmentsget help payingget alerts
Which medicines are FDA-approved for ALK-Positive Lung Cancer?
There are currently 7 FDA-approved medications for ALK-Positive Lung Cancer.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
How to get help paying for ALK-Positive Lung Cancer treatment
Charity funds and drugmaker programs for ALK-Positive Lung Cancer, checked at the source.
No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.
- Nelkarmi (Neladalkib) · Nuvalent Patient Support
- Lorbrena (Lorlatinib) · Pfizer Oncology Together
- Alecensa (Alectinib) · Genentech Access Solutions
- Alunbrig (Brigatinib) · Takeda Oncology Here2Assist
- Ensacove (Ensartinib) · XcoveryCares
- Xalkori (Crizotinib) · Pfizer Oncology Together
- Zykadia (Ceritinib) · Novartis Oncology Universal Co-pay Program
Every program and fund for ALK-Positive Lung Cancer, by insurance →
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for ALK-Positive Lung Cancer
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted ALK-Positive Lung Cancer resources
Reputable organizations and medical references for learning more about ALK-Positive Lung Cancer, including disease registries, foundation resources, and clinical guidelines.
- National Cancer Institute - Non-Small Cell Lung Cancer Treatment (PDQ), Health Professional Version
- National Cancer Institute - Non-Small Cell Lung Cancer Treatment (PDQ), Patient Version
- American Cancer Society - Targeted Drug Therapy for Non-small Cell Lung Cancer
- American Cancer Society - Lung Cancer Statistics
- American Cancer Society - What Is Lung Cancer?
- LUNGevity - About ALK-positive Lung Cancer (Navigating ALK)
- ALK Positive - Lung and Other ALK-positive Cancers
- ALK Positive - Testing and Diagnosing ALK+ Cancer
- Alecensa (alectinib) prescribing information (DailyMed)
- Rangachari et al., Lung Cancer 2015 - Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers
- Gainor et al., Cancer Discovery 2016 - Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- FDA - FDA grants accelerated approval to neladalkib for previously treated locally advanced or metastatic ALK-positive non-small cell lung cancer